SecBot SecBot
SECBOTREPLAY Home › Report › ONCY

ONCY · Oncolytics Biotech announced a scheduled Type C meeting with the FDA on…

ONCOLYTICS BIOTECH INC · 8-K filed Apr 6, 2026 at 09:24 ET

At the news

BULLISHIMPACT 6/10

8-K filed Apr 6, 2026 at 09:24 ET

Oncolytics Biotech announced a scheduled Type C meeting with the FDA on April 16, 2026, to discuss a registrational pathway for pelareorep in combination with a checkpoint inhibitor for squamous cell anal carcinoma (SCAC). The company plans to propose a single-arm pivotal study enrolling 60–70 patients with objective response rate as the primary endpoint, supported by clinical data showing approximately 30% ORR and 17-month median duration of response.

  • Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss a registrational pathway for pelareorep in SCAC.
  • The proposed pivotal study is single-arm, enrolling 60–70 patients, with objective response rate (ORR) as the primary endpoint.
  • Clinical data from Cohort 4 of the GOBLET study showed approximately 30% ORR and 17-month median duration of response in late-line SCAC patients.
  • SCAC is a rare cancer with limited second-line treatment options, positioning pelareorep for a potentially efficient approval path.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access